What's Happening?
Oregon Health & Science University (OHSU) has been awarded an $8 million grant from the National Institutes of Health (NIH) to establish a state-of-the-art Biosafety Level 3 (BSL-3) laboratory. This funding, provided through the NIH’s C06 Research Facilities
Construction program, will support the renovation of existing research space on OHSU’s Marquam Hill campus into a modern, high-containment facility. The new BSL-3 laboratory is designed to enhance research capabilities for dangerous pathogens and emerging infectious diseases. This initiative aims to replace OHSU’s current BSL-3 laboratory, which was constructed over 30 years ago and has become inadequate for contemporary infectious disease research needs. Fikadu Tafesse, Ph.D., professor and chair of microbiology and immunology in the OHSU School of Medicine, led the successful grant application effort, emphasizing the critical need for a larger and safer facility, especially in light of recent pandemics.
Why It's Important?
This investment is crucial for bolstering the United States' preparedness against future infectious disease outbreaks. The COVID-19 pandemic highlighted significant gaps in research infrastructure, making the modernization of facilities like OHSU's BSL-3 lab a national priority. By enabling cutting-edge research on emerging and re-emerging pathogens, the new laboratory will contribute to a deeper understanding of how these diseases spread and how to develop effective countermeasures. This will directly impact public health by accelerating the development of vaccines and treatments. Furthermore, the expanded capacity and advanced design of the facility will attract leading scientists and foster collaborations, strengthening the nation's overall infectious disease research portfolio and ensuring a more robust response to health threats.
What's Next?
The new BSL-3 laboratory will be situated on the seventh floor of OHSU’s Richard Jones Hall, with construction anticipated to take approximately three years to complete. Once operational, the facility will serve as a vital institutional resource for OHSU investigators and a regional asset for research partners who lack access to their own BSL-3 laboratories. The design includes four dedicated research suites, two animal research suites, shared equipment areas, and facilities for new approach methodologies (NAMs), such as organoids and advanced human tissue models. These NAMs are expected to reduce reliance on animal studies and accelerate the understanding of human health outside clinical settings, providing critical information for fighting diseases and preparing for future outbreaks.
Beyond the Headlines
The establishment of this advanced BSL-3 laboratory signifies a long-term strategic shift in how the U.S. approaches infectious disease research and pandemic preparedness. Beyond its immediate scientific benefits, the facility addresses ethical considerations by incorporating NAMs, which aim to reduce animal testing. It also underscores a cultural recognition of the ongoing threat posed by emerging pathogens, moving beyond reactive responses to proactive infrastructure development. This investment reflects a commitment to scientific discovery and collaboration, positioning OHSU as a key player in national and global health security. The ability to conduct comprehensive research, from initial pathogen study to potential treatment development, within a single, modern facility will streamline processes, reduce costs, and ultimately enhance the nation's resilience against future health crises.
